Boehringer Ingelheim’s top-selling drug lifted sales in the first half, as the German drugmaker gears up to file for U.S. approval of a new obesity medicine.
Source link
About The Author
Boehringer Ingelheim Posts Sales Growth as Obesity Drug Filing Awaits